Caris Life Sciences (CAI) Cash & Equivalents (2024 - 2026)

Caris Life Sciences' Cash & Equivalents history runs 3 years deep, the most recent figure standing at $821.1 million for Q1 2026.

• In Q1 2026, Cash & Equivalents changed N/A year-over-year to $821.1 million; the TTM figure through Mar 2026 stood at $821.1 million (changed N/A YoY), while the FY2025 annual figure was $797.8 million, up 1119.09% from the prior year.
• Cash & Equivalents was $821.1 million for Q1 2026 at Caris Life Sciences, up from $797.8 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $821.1 million in Q1 2026 to a low of $65.4 million in Q4 2024.
• Historically, Cash & Equivalents has averaged $631.9 million across 3 years, with a median of $754.7 million in 2025.
• Biggest YoY gain for Cash & Equivalents was 1119.09% in 2025; the steepest drop was 1119.09% in 2025.
• A 3-year view of Cash & Equivalents shows it stood at $65.4 million in 2024, then jumped by 1119.09% to $797.8 million in 2025, then increased by 2.93% to $821.1 million in 2026.
• The last three Cash & Equivalents figures came in at $821.1 million (Q1 2026), $797.8 million (Q4 2025), and $754.7 million (Q3 2025), per Business Quant data.